PL3620171T3 - Przeciwciała anty-gm-csf i ich zastosowania - Google Patents

Przeciwciała anty-gm-csf i ich zastosowania

Info

Publication number
PL3620171T3
PL3620171T3 PL19180152.1T PL19180152T PL3620171T3 PL 3620171 T3 PL3620171 T3 PL 3620171T3 PL 19180152 T PL19180152 T PL 19180152T PL 3620171 T3 PL3620171 T3 PL 3620171T3
Authority
PL
Poland
Prior art keywords
applications
csf antibodies
csf
antibodies
Prior art date
Application number
PL19180152.1T
Other languages
English (en)
Inventor
Stefan Steidl
Elisabeth Thomassen-Wolf
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of PL3620171T3 publication Critical patent/PL3620171T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243Colony Stimulating Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL19180152.1T 2005-05-18 2006-05-17 Przeciwciała anty-gm-csf i ich zastosowania PL3620171T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68200905P 2005-05-18 2005-05-18

Publications (1)

Publication Number Publication Date
PL3620171T3 true PL3620171T3 (pl) 2022-08-08

Family

ID=37114333

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19180152.1T PL3620171T3 (pl) 2005-05-18 2006-05-17 Przeciwciała anty-gm-csf i ich zastosowania
PL06742970T PL1888643T3 (pl) 2005-05-18 2006-05-17 Przeciwciała przeciwko GM-CSF i ich zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06742970T PL1888643T3 (pl) 2005-05-18 2006-05-17 Przeciwciała przeciwko GM-CSF i ich zastosowania

Country Status (26)

Country Link
US (5) US7867495B2 (pl)
EP (4) EP1888643B1 (pl)
JP (2) JP5295759B2 (pl)
KR (1) KR101308087B1 (pl)
CN (2) CN103087190B (pl)
AR (1) AR053608A1 (pl)
AU (1) AU2006249062B2 (pl)
BR (1) BRPI0610796B8 (pl)
CA (1) CA2608498C (pl)
CY (2) CY1115920T1 (pl)
DK (2) DK3620171T3 (pl)
ES (2) ES2918209T3 (pl)
HR (2) HRP20150023T1 (pl)
HU (1) HUE058876T2 (pl)
IL (1) IL187375A (pl)
LT (1) LT3620171T (pl)
ME (1) ME02059B (pl)
NO (1) NO344992B1 (pl)
NZ (1) NZ564027A (pl)
PL (2) PL3620171T3 (pl)
PT (2) PT3620171T (pl)
RS (2) RS53743B1 (pl)
RU (1) RU2447085C2 (pl)
SI (2) SI1888643T1 (pl)
TW (1) TWI477512B (pl)
WO (1) WO2006122797A2 (pl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1874819B1 (en) 2005-04-18 2015-05-27 Amgen Research (Munich) GmbH Antibody neutralizers of human granulocyte macrophage colony stimulating factor
HUE058876T2 (hu) * 2005-05-18 2022-09-28 Morphosys Ag Anti-GM-CSF antitestek és felhasználásuk
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分
ES2609088T3 (es) * 2006-02-08 2017-04-18 Morphotek, Inc. Péptidos GM-CSF antigénicos y anticuerpos anti-GM-CSF
US20080171038A1 (en) * 2006-11-08 2008-07-17 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
US20080206241A1 (en) 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
EP2160407A4 (en) * 2007-05-23 2011-07-27 Crc For Asthma And Airways Ltd NEUTRALIZING ANTIBODIES
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US20100297135A1 (en) * 2007-11-12 2010-11-25 Crc For Asthma And Airways Ltd. Epitope for neutralizing antibodies
PT2215119E (pt) 2007-11-13 2013-02-11 Boehringer Ingelheim Int Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem
PL2215121T3 (pl) 2007-11-26 2016-07-29 Bayer Ip Gmbh Przeciwciała przeciwko mezotelinie i ich zastosowania
EP2088432A1 (en) * 2008-02-11 2009-08-12 MorphoSys AG Methods for identification of an antibody or a target
AU2009243184B2 (en) * 2008-04-28 2015-06-04 Humanigen, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
US8455623B2 (en) 2008-05-21 2013-06-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
KR20110044991A (ko) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 TNF-α 길항제 다-표적 결합 단백질
EP3056217B1 (en) * 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
KR101761324B1 (ko) * 2008-12-22 2017-07-25 더 유니버시티 오브 멜버른 통증 치료
CA2759506A1 (en) * 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
JP2012530047A (ja) * 2009-05-05 2012-11-29 モルフォシス・アー・ゲー 多発性硬化症のための治療
KR20140061379A (ko) * 2011-07-06 2014-05-21 모르포시스 아게 항­cd20 및 항­gm­csf 항체의 치료 조합물 및 이의 용도
US9901079B2 (en) * 2011-08-18 2018-02-27 New York University Inhibition of oncogenic kras-induced GM-CSF production and function
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
CA2871417C (en) 2012-04-23 2021-08-31 Genefrontier Corporation Anti-human cd69 antibody, and use thereof for medical purposes
ES2734130T3 (es) 2012-08-17 2019-12-04 Morphosys Ag Anticuerpos específicos de complejos y fragmentos de anticuerpo y su uso
KR20150056846A (ko) * 2012-09-20 2015-05-27 모르포시스 아게 류마티스 관절염에 대한 치료
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーTakeda GmbH Gm−csf中和化合物を含む凍結乾燥製剤
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
AU2013342779B2 (en) 2012-11-09 2019-09-26 Genefrontier Corporation Anti-ADAM28 antibody for treating cancer
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
AU2014314053C1 (en) 2013-08-30 2023-11-02 Takeda Pharmaceutical Company Limited Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
JP6202339B2 (ja) 2013-12-19 2017-09-27 国立研究開発法人国立精神・神経医療研究センター GM−CSF産生T細胞制御剤、及びTh1/Th2免疫バランス調節剤
CN106659785B (zh) 2014-05-07 2021-04-30 武田有限公司 包含gm-csf中和化合物的液体制剂
JP6490419B2 (ja) * 2014-12-24 2019-03-27 学校法人関西医科大学 制御性t細胞分化誘導剤
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
WO2016143702A1 (ja) 2015-03-06 2016-09-15 ジーンフロンティア株式会社 抗ヒト膜型adam28抗体
KR101953706B1 (ko) * 2016-09-19 2019-03-05 아이-맵 항-gm-csf 항체 및 이것의 사용
CN107840886B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US11673962B2 (en) 2017-10-02 2023-06-13 Humanigen, Inc. Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2020078270A1 (en) 2018-10-15 2020-04-23 Elixiron Immunotherapeutics (hong Kong) Limited Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
JP7495403B2 (ja) 2018-11-09 2024-06-04 キニクサ ファーマシューティカルズ, リミテッド 巨細胞性動脈炎の治療
CN113677356A (zh) * 2019-01-07 2021-11-19 湖南思为康医药有限公司 用于降低毒性的共表达嵌合抗原受体和il-6拮抗剂的修饰免疫细胞及其在过继细胞疗法中的用途
US20220331425A1 (en) 2019-06-03 2022-10-20 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
US20210284744A1 (en) 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2022093855A1 (en) 2020-10-26 2022-05-05 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
NL2036015B1 (en) 2023-10-12 2025-04-30 Micronit Holding B V A method of manufacturing a nozzle assembly, comprising weakening a wafer at at least two focal zones in the depth direction by focusing a laser beam
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5747032A (en) 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
ES2176484T3 (es) * 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
EP1144607B1 (en) 1999-07-20 2008-12-17 MorphoSys AG Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
ES2365606T3 (es) 2002-02-13 2011-10-07 Ludwig Institute For Cancer Research Ltd. Anticuerpos contra gm-csf quiméricos.
US7754450B2 (en) 2002-11-15 2010-07-13 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
HUE058876T2 (hu) * 2005-05-18 2022-09-28 Morphosys Ag Anti-GM-CSF antitestek és felhasználásuk

Also Published As

Publication number Publication date
JP5295759B2 (ja) 2013-09-18
BRPI0610796A2 (pt) 2010-11-09
EP3620171B1 (en) 2022-04-20
US20200024340A1 (en) 2020-01-23
LT3620171T (lt) 2022-06-10
US20170218061A1 (en) 2017-08-03
AU2006249062A1 (en) 2006-11-23
CN103087190B (zh) 2016-08-03
PT3620171T (pt) 2022-06-30
US10377820B2 (en) 2019-08-13
US7867495B2 (en) 2011-01-11
ES2918209T3 (es) 2022-07-14
IL187375A (en) 2012-06-28
US20110045000A1 (en) 2011-02-24
SI1888643T1 (sl) 2015-03-31
US20210347879A1 (en) 2021-11-11
ME02059B (me) 2015-05-20
EP2468773A3 (en) 2012-09-19
RS53743B1 (sr) 2015-06-30
SI3620171T1 (sl) 2022-09-30
ES2527428T3 (es) 2015-01-23
RU2007147870A (ru) 2009-06-27
PT1888643E (pt) 2015-01-14
CY1125427T1 (el) 2025-05-09
DK1888643T3 (en) 2015-01-05
CY1115920T1 (el) 2017-01-25
HK1114620A1 (en) 2008-11-07
DK3620171T3 (da) 2022-06-07
US9751939B2 (en) 2017-09-05
US20090053213A1 (en) 2009-02-26
US11028165B2 (en) 2021-06-08
WO2006122797A2 (en) 2006-11-23
RU2447085C2 (ru) 2012-04-10
CN101218255B (zh) 2013-01-09
NO20076437L (no) 2007-12-13
KR101308087B1 (ko) 2013-10-16
AR053608A1 (es) 2007-05-09
HRP20150023T1 (hr) 2015-02-27
EP1888643A2 (en) 2008-02-20
KR20080015008A (ko) 2008-02-15
TWI477512B (zh) 2015-03-21
JP2013116912A (ja) 2013-06-13
BRPI0610796B1 (pt) 2020-01-21
JP2008545632A (ja) 2008-12-18
WO2006122797A3 (en) 2007-02-15
EP2468773A2 (en) 2012-06-27
BRPI0610796B8 (pt) 2021-05-25
NO344992B1 (no) 2020-08-17
EP3620171A1 (en) 2020-03-11
WO2006122797B1 (en) 2007-04-19
AU2006249062B2 (en) 2012-12-20
HRP20220755T3 (hr) 2022-09-02
IL187375A0 (en) 2008-02-09
CN103087190A (zh) 2013-05-08
RS63382B1 (sr) 2022-08-31
CN101218255A (zh) 2008-07-09
EP3150221A1 (en) 2017-04-05
CA2608498A1 (en) 2006-11-23
TW200716674A (en) 2007-05-01
HUE058876T2 (hu) 2022-09-28
JP5769744B2 (ja) 2015-08-26
EP1888643B1 (en) 2014-10-29
PL1888643T3 (pl) 2015-04-30
NZ564027A (en) 2011-06-30
CA2608498C (en) 2017-04-04

Similar Documents

Publication Publication Date Title
PL3620171T3 (pl) Przeciwciała anty-gm-csf i ich zastosowania
HUS2100053I1 (hu) Interleukin-13-antitest-készítmény
CY2019041I2 (el) Τροποποιημενα αντισωματα εναντι il-23
DK2059535T3 (da) Prlr-specifikt antistof og anvendelser deraf
DK1904104T3 (da) SP35-antistoffer og anvendelser heraf
DK1994055T3 (da) Anti-5t4-antistoffer og anvendelser deraf
NO20190202A1 (no) Anvendelse av anti-CGRP antagonist antistoff
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
NO20076607L (no) TWEAK - bindende antistoff
LTPA2016026I1 (lt) Anti-il-17 antikūnai
HRP20150176T1 (xx) Protutijela protiv miostatina
DK1964852T3 (da) Anti-ilt7-antistof
NO20071430L (no) Anti-OX4OL antistoffer
DK2993187T3 (da) Antistoffer rettet mod her-3 og anvendelser deraf
DK2068887T3 (da) SP35-antistoffer og anvendelser heraf
DK1971366T3 (da) Humane anti-IL-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
DK2907827T3 (da) Humaniserede anti-faktor D-antistoffer og anvendelser deraf
DK1599504T3 (da) Modificeret antistof
CY2013046I2 (el) Καινοτομος χρηση των αντισωματων αντι il-1bhta
DE602006017373D1 (de) Madcam-antikörper
DE602005017080D1 (de) Toner und tonerherstellungsprozess
NO20082454L (no) Anti-alfa2 integrin antistoffer og deres anvendelser
DK1979378T3 (da) Ny samling af HCDR3 områder og anvendelser derfor
DE602006020117D1 (de) Nadellager und herstellungsverfahren dafür
EP1955844A4 (en) COMPOSITE SHEET AND USE THEREOF